New treatment options for patients with metastatic castration-resistant prostate cancer

Cancer Treatment Reviews

Volumn 38, Issue 5, 2012, Pages 340-345

  Higano, Celestia S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Abiraterone; Cabazitaxel; Chemotherapy; Denosumab; Docetaxel; Metastatic castration resistant prostate cancer; Mitoxantrone; Radium 223; Sipuleucel T; Treatment paradigm

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; AFLIBERCEPT; ALKALINE PHOSPHATASE; BICALUTAMIDE; CABAZITAXEL; CUSTIRSEN; CYPROTERONE ACETATE; DASATINIB; DENOSUMAB; DIETHYLSTILBESTROL; DOCETAXEL; FLUTAMIDE; IPILIMUMAB; KETOCONAZOLE; LENALIDOMIDE; MITOXANTRONE; NILUTAMIDE; ORTERONEL; PLACEBO; PREDNISONE; RADIUM CHLORIDE RA 223; SIPULEUCEL T; ZOLEDRONIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHILL; DIARRHEA; DRUG FEVER; DRUG INDUCED HEADACHE; EDEMA; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; JAW OSTEONECROSIS; KIDNEY FUNCTION; LEUKAPHERESIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THERAPY DELAY;

ANDROSTENOLS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TAXOIDS; TISSUE EXTRACTS;

EID: 84861200384     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.07.007     Document Type: Review

References (48)

1. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005, 23:8253-8261.
2. Rosenberg J.E., Weinberg V.K., Kelly W.K., et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007, 110:556-563.
3. Higano C.S., Schellhammer P.F., Small E.J., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115:3670-3679.
4. Haines A.M., Larkin S.E., Richardson A.P., Stirling R.W., Heyderman E. A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer 1989, 60:887-892.
5. Goldstein N.S. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002, 117:471-477.
6. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
7. Higano CS, Small EJ, Schellhammer PF, et al. Predictors of outcome and subgroup results from the integrated analysis of sipuleucel-T trials in metastatic castration-resistant prostate cancer. Presented at: Annual Meeting of the American Society of Clinical Oncology (ASCO); June 4-8, 2010; Chicago, IL. [Abstract 2550].
8. Butterfield L.H., Disis M.L., Khleif S.N., Balwit J.M., Marincola F.M. Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med 2010, 8:130.
9. Beer T.M., Bernstein G.T., Corman J.M., et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-t in androgen-dependent prostate cancer. Clin Cancer Res 2011.
10. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
11. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
12. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008, 26:242-245.
13. Scher H.I., Jia X., Chi K., et al. Randomized, open-label phase iii trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011, 29:2191-2198.
14. Small E, Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Presented at: 2009 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium; February 26-28, 2009; Orlando, FL. [Abstract 7].
15. AstraZeneca PLC Second Quarter and Half Year Results 2011. Available from: http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3DNarrativepdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285625798907&ssbinary=true.
16. Kelly W.K., Halabi S., Carducci M.A., et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 2010, 28(18s):LBA4511.
17. S0421 closes early; interim analysis finds no benefit in adding atrasentan to prostate chemotherapy. Available from: http://www.swog.org/visitors/newsletters/2011/04/index.asp?a=s0421.
18. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
19. Attard G., Greystroke A., Kaye S., de Bono J. Update on tubulin binding agents. Pathol Biol (Paris) 2006, 54:72-84.
20. Alter A.W., Kraus L.A., Bissery M.-C. In vitro activity of TXD258 in chemotherapeutic resistant tumour cell lines. Proc Am Assoc Cancer Res 2000, 41:303.
21. Bissery M.-C., Bouchard H., Riou J.F., et al. Preclinical evaluation of TXD258, a new taxoid. Proc Am Assoc Cancer Res 2000, 41:214.
22. Potter G.A., Barrie S.E., Jarman M., Rowlands M.G. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17, 20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem. 1995, 38:2463-2471.
23. Barrie S.E., Haynes B.P., Potter G.A., Chan F.C., Goddard P.M., Dowsett M., et al. Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. J Steroid Biochem Mol Biol 1997, 60:347-351.
24. Jarman M., Barrie S.E., Llera J.M. The 16, 17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. J Med Chem 1998, 41:5375-5381.
25. de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
26. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-882.
27. Fizazi K., Carducci M., Smith M., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
28. Henriksen G., Breistol K., Bruland O.S., et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002, 62:3120-3125.
29. Henriksen G., Fisher D.R., Roeske J.C., et al. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med 2003, 44:252-259.
30. Nilsson S., Larsen R.H., Fossa S.D., et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005, 11:4451-4459.
31. Nilsson S., Franzen L., Parker C., et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007, 8:587-594.
32. Algeta announces positive preliminary bone marker results in a phase IIa study evaluating Alpharadin in breast cancer patients with bone metastases. Available from: http://www.algeta.com/xml_press_underside.asp?xml=http://cws.huginonline.com/A/134655/PR/201106/1521593.xml&m=34572&s=34686&ss=&d=2011-06-07.
33. Alpharadin Significantly Improves Overall Survival in Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone. Available from: http://www.press.bayer.com/baynews/baynews.nsf/ID/7D32B5B6B39B6D40C12578A70016AB9A.
34. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
35. Scher H.I., Beer T.M., Higano C.S., et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375:1437-1446.
36. Higano CS, Beer TM, Taplin M, et al. Antitumor activity of MDV3100 in pre- and post-docetaxel advanced prostate cancer: Long-term follow-up of a phase I/II study. J Clin Oncol 2011; 29 (Suppl. 7). [ASCO abstract 134].
37. Dreicer R, Agus DB, MacVicar GR, MacLean D, Zhang T, Stadler WM. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: a phase I/II, open-label study. Presented at: 2010 American Society of Clinical Oncology (ASCO) Genitourinary Congress, March 5-7, 2010, San Francisco, CA. [Abstract 103].
38. Beer TM, Slovin SF, Higano CS, et al. Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). Presented at: Annual Meeting of the American Society of Clinical Oncology (ASCO); May 30-June 3, 2008; Chicago, IL. [Abstract 5004].
39. Slovin S.F., Beer T.M., Higano C.S., Tejwani S., Hamid O., Picus J., et al. Prostate cancer clinical trials consortium. Initial phase II experience of ipilimumab alone and in combination with radiotherapy in patients with metastatic castration resistant prostate cancer. J Clin Oncol 2009, 27:5138. (15s).
40. Tollefson MK, Karnes RJ, Thompson RH, et al. A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer. Presented at: 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA. [Abstract 168].
41. Demaria S., Bhardwaj N., McBride W.H., Formenti S.C. Combining radiotherapy and immunotherapy: a revived partnership. Int J Rad Onc Bio Phys 2005, 63:655-666.
42. Nelson J.B., Chan-Tack K., Hedican S.P., et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996, 56:663-668.
43. Weydert C.J., Esser A.K., Mejia R.A., Drake J.M., Barnes J.M., Henry M.D. Endothelin-1 inhibits prostate cancer growth in vivo through vasoconstriction of tumor-feeding arterioles. Cancer Biol Ther 2009, 8:720-729.
44. Yin J.J., Mohammad K.S., Käkönen S.M., et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003, 100:10954-10959.
45. Carducci M.A., Saad F., Abrahamsson P.A., et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007, 110:1959-1966.
46. Nelson J.B., Love W., Chin J.L., et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008, 113:2478-2487.
47. Results of zibotentan phase III trial in castration resistant prostate cancer. Available from: 2010. http://www.astrazeneca.com/Media/Press-releases/Article/Results-of-Zibotentan-Phase-III-trial-in-castration-resistant-pr.
48. de Bono J.S., Scher H.I., Montgomery R.B., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008, 14:6302-6309.